Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1
3(100.0%)
3Total
Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT06742593Phase 1Not Yet Recruiting

Study of MT027 in Patients with Brain, Meninges, and Spinal Cord Metastatic Solid Tumors

Role: lead

NCT06737146Phase 1Not Yet Recruiting

Study of MT027 in Patients with Recurrent or Progressive High-grade Glioma

Role: lead

NCT06726564Phase 1Recruiting

A Study of MT027 in Patients with Pleural Malignant Tumors

Role: lead

All 3 trials loaded